Physician profile
Robert D Marks
NPI 1972541910
$8,022.52
in general payments reported to CMS, 2019-2025
34 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $497 · 2021: $1,062 · 2022: $1,227 · 2023: $1,166 · 2024: $1,796 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.42 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,031.59 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Abbvie INC. | $1,971.86 | 2019-2025 | |
| Janssen Biotech, INC. | $1,368.59 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $457.85 | 2019-2025 | Entyvio |
| Pfizer INC. | $285.26 | 2023-2025 | |
| Lilly USA, LLC | $181.08 | 2024-2025 | Omvoh |
| Celgene Corporation | $178.28 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $162.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $154.86 | 2025 | Ibsrela |
| Genzyme Corporation | $147.44 | 2022-2025 | |
| Qol Medical, LLC | $124.49 | 2021-2025 | Sucraid |
| Romark Laboratories, Lc | $122.26 | 2019 | |
| Lucid Diagnostics INC. | $112.75 | 2024 | |
| Phathom Pharmaceuticals, INC. | $110.01 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $59.96 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $59.18 | 2021-2022 | |
| Celltrion USA INC. | $57.92 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $56.35 | 2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $49.37 | 2020-2022 | |
| Allergan, INC. | $42.89 | 2019 | |
| Gilead Sciences, INC. | $41.95 | 2019-2021 | |
| Evoke Pharma, INC. | $36.73 | 2021-2024 | |
| Conmed Corporation | $25.91 | 2024 | Conmed Biliary, Conmed Hemostasis |
| Medtronic USA, INC. | $24.69 | 2019 | |
| Braintree Laboratories, INC. | $24.52 | 2024 | Suflave, Sutab |
| Fujifilm Healthcare Americas Corporation | $19.44 | 2020 | |
| Alfasigma USA, INC. | $16.75 | 2020 | |
| Exact Sciences Corporation | $15.26 | 2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $15.08 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.79 | 2021 | |
| Ucb, INC. | $14.33 | 2019 | |
| Intra-Sana Laboratories | $14.01 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.44 | 2022 | |
| Boston Scientific Corporation | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.